Alzheimer's disease Trials in Stockholm, Sweden
Conditions / Alzheimer's disease / Stockholm, Sweden
Research into Alzheimer's disease spans multiple therapeutic approaches and trial phases.
51 total trials for this combination
Showing top 10 of 51 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04445831 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease | COMPLETED | PHASE1/PHASE2 |
| NCT02484547 | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | TERMINATED | PHASE3 |
| NCT01900665 | Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo | TERMINATED | PHASE3 |
| NCT02670083 | A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). | TERMINATED | PHASE3 |
| NCT00594568 | Effect of LY450139 on the Long Term Progression of Alzheimer's Disease | COMPLETED | PHASE3 |
| NCT01767311 | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | COMPLETED | PHASE2 |
| NCT02760602 | A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease | TERMINATED | PHASE3 |
| NCT03289143 | A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease | TERMINATED | PHASE2 |
| NCT05310071 | A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease | TERMINATED | PHASE3 |
| NCT04241068 | A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 | TERMINATED | PHASE3 |